QSAR modeling, molecular docking, ADMET prediction and molecular dynamics simulations of some 6-arylquinazolin-4-amine derivatives as DYRK1A inhibitors

被引:17
|
作者
Khamouli, Saida [1 ]
Belaidi, Salah [1 ]
Bakhouch, Mohamed [2 ,3 ]
Chtita, Samir [4 ]
Hashmi, Md Amiruddin [5 ]
Qais, Faizan Abul [6 ]
机构
[1] Univ Biskra, LMCE Lab, Grp Computat & Pharmaceut Chem, BP 145, Biskra 07000, Algeria
[2] Chouaib Doukkali Univ, Fac Sci, Dept Chem, Lab Bioorgan Chem, POB 24, M-24000 Jadida, Morocco
[3] Univ Sidi Mohamed Ben Abdellah, Fac Sci Dhar Mahraz, Engn Lab Organometall & Mol Mat & Environm, POB Atlas 1796, Fes 30000, Morocco
[4] Hassan II Univ Casablanca, Fac Sci Ben MSik, Lab Analyt & Mol Chem, Box 7955, Casablanca, Chile
[5] Aligarh Muslim Univ, Fac Life Sci, Interdisciplinary Biotechnol Unit, Aligarh 202002, Uttar Pradesh, India
[6] Aligarh Muslim Univ, Fac Agr Sci, Dept Agr Microbiol, Aligarh 202002, Uttar Pradesh, India
关键词
DYRK1A; 6-arylquinazolin-4-amine; QSAR; MolecularDocking; ADMET; Molecular dynamics; DRUG DISCOVERY; DOWN-SYNDROME; KINASES; DISEASE; SPECIFICITY; GROMACS; FAMILY; SERIES;
D O I
10.1016/j.molstruc.2022.132659
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) is a protein kinase with diverse functions in neuronal development and adult brain physiology. QSAR study was performed for a diverse set of thirty-three6-arylquinazolin-4-amine derivatives as DYRK1A inhibitors. The QSAR model with HOMO, LUMO, qC(sub), SAG and MW descriptors showed satisfactory internal and external validation parameters (R-train(2) = 0.867,R-adj(2)= 0.831, Q(LOO)(2)= 0.755, F = 24 . 682 and R-pred (2)= 0.856). The excellent statistical results obtained for the developed model, strongly suggest that the model is reasonable for the prediction of the activity of new inhibitors. Therefore, we have designed several new potent DYRK1A inhibitors and validated their inhibitory activity by molecular docking methods using Autodock tools. Based in silico analysis, two novel compounds N2 and N11have been designed, which they have been identified hydrophobic and hydrogen bonds, with the binding pockets of active site4YLJ. Furthermore, the two newly designed compounds exhibited good ADMET properties, their molecular dynamics studies have shown a favorable energetic state and dynamic stability, characterized by root mean square deviation (RMSD), root mean square fluctuation (RMSF) and hydrogen bond. The outcomes of this study can be used to show the interest of DYRK1A inhibition for Alzheimer treatment. (C)& nbsp;2022 Published by Elsevier B.V.& nbsp;
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Pharmacophore Based 3D-QSAR Modeling and Molecular Docking of Leucettines as Potent Dyrk1A Inhibitors
    Bahl, Anu
    Joshi, Prashant
    Bharate, Sandip B.
    Chopra, Harish
    LETTERS IN DRUG DESIGN & DISCOVERY, 2013, 10 (08) : 719 - 726
  • [2] Multi-combined QSAR, molecular docking, molecular dynamics simulation, and ADMET of Flavonoid derivatives as potent cholinesterase inhibitors
    Soufi, Hatim
    Moussaoui, Mohamed
    Baammi, Soukayna
    Baassi, Mouna
    Salah, Mohammed
    Daoud, Rachid
    El Allali, Achraf
    Belghiti, M. E.
    Moutaabbid, Mohammed
    Belaaouad, Said
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (12): : 6027 - 6041
  • [3] Integrative Approach for Designing Novel Triazole Derivatives as α-Glucosidase Inhibitors: QSAR, Molecular Docking, ADMET, and Molecular Dynamics Investigations
    Abchir, Oussama
    Khedraoui, Meriem
    Nour, Hassan
    Yamari, Imane
    Errougui, Abdelkbir
    Samadi, Abdelouahid
    Chtita, Samir
    PHARMACEUTICALS, 2024, 17 (02)
  • [4] Rational design of some 1,3,4 trisubstituted pyrazole-thiazole derivatives to serve as MtInhA inhibitors using QSAR, ADMET, molecular docking, MM-GBSA, and molecular dynamics simulations approach
    Mhetre, Neha M.
    Bhatambrekar, Aniket L.
    Priya, D.
    Saravanan, Venkatesan
    Kathiravan, Muthukumaradoss
    Shevate, Krishna S.
    Rajagopal, Kalirajan
    Asgaonkar, Kalyani D.
    Chitre, Trupti S.
    CHEMICAL PHYSICS IMPACT, 2024, 9
  • [5] Design of novel DABO derivatives as HIV-1 RT inhibitors using molecular docking, molecular dynamics simulations and ADMET properties
    Zhang, Yanjun
    Chen, Lu
    Wang, Zhonghua
    Zhu, Yiren
    Jiang, Huifang
    Xu, Jie
    Xiong, Fei
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 42 (08): : 4196 - 4213
  • [6] Design of vilazodone-donepezil chimeric derivatives as acetylcholinesterase inhibitors by QSAR, molecular docking and molecular dynamics simulations
    Guo, Liyuan
    Chang, Zelei
    Tong, Jianbo
    Gao, Peng
    Zhang, Yakun
    Liu, Yuan
    Yang, Yulu
    Wang, Chunying
    PHYSICAL CHEMISTRY CHEMICAL PHYSICS, 2024, 26 (26) : 18149 - 18161
  • [7] QSAR modeling, molecular docking studies and ADMET prediction on a series of phenylaminopyrimidine-(thio) urea derivatives as CK2 inhibitors
    Goudzal, Amina
    El Aissouq, Abdellah
    El Hamdani, Hicham
    Ouammou, Abdelkrim
    MATERIALS TODAY-PROCEEDINGS, 2022, 51 : 1851 - 1862
  • [8] 3D-QSAR modeling, molecular docking and ADMET properties of benzothiazole derivatives as a-glucosidase inhibitors
    Khaldan, Ayoub
    Bouamrane, Soukaina
    El-mernissi, Reda
    Maghat, Hamid
    Ajana, Mohammed Aziz
    Sbai, Abdelouahid
    Bouachrine, Mohammed
    Lakhlifi, Tahar
    MATERIALS TODAY-PROCEEDINGS, 2021, 45 : 7643 - 7652
  • [9] QSAR modelling, molecular docking, molecular dynamic and ADMET prediction of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors
    Aloui, Mourad
    Er-rajy, Mohammed
    Imtara, Hamada
    Goudzal, Amina
    Zarougui, Sara
    El Fadili, Mohamed
    Arthur, David E.
    Mothana, Ramzi A.
    Noman, Omar M.
    Tarayrah, Mahmoud
    Menana, Elhalaoui
    SAUDI PHARMACEUTICAL JOURNAL, 2024, 32 (01)
  • [10] Molecular modelling studies of quinazolinone derivatives as MMP-13 inhibitors by QSAR, molecular docking and molecular dynamics simulations techniques
    Huang, Shanshan
    Feng, Kairui
    Ren, Yujie
    MEDCHEMCOMM, 2019, 10 (01) : 101 - 115